{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:38:54Z","timestamp":1794011934783,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The field of medicine is constantly changing and, as healthcare providers, we are fortunate to be practicing in a time when patients are living longer and novel therapeutic options continue to evolve. However, these new advances may be associated with adverse effects that practitioners need to be aware of. Some of these impair the immune system leading to secondary immunodeficiencies (SID) that increase host susceptibility to infections and other complications. The causes and consequences of these SID are extremely broad, and a detailed review is beyond the scope of this article. The goal of this primer is to provide a general overview and understanding of common conditions and therapies leading to SID, as well as a guide to the assessment and management of patients with SID.<\/jats:p>","DOI":"10.1186\/s13223-024-00925-4","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T19:29:42Z","timestamp":1738006182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Secondary Immunodeficiency"],"prefix":"10.1186","volume":"20","author":[{"given":"Persia","family":"Pourshahnazari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Betschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vy. H. D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Waserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongbo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"issue":"6","key":"925_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.anai.2021.08.413","volume":"127","author":"KS Tuano","year":"2021","unstructured":"Tuano KS, Seth N, Chinen J. Secondary immunodeficiencies: an overview. Ann Allergy Asthma Immunol. 2021;127(6):617\u201326.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"925_CR2","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","volume":"149","author":"IM Otani","year":"2022","unstructured":"Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees. J Allergy Clin Immunol. 2022;149(5):1525\u201360.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"925_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Allen","year":"2017","unstructured":"Allen C, Barber C, Barregard RM, Bhutta L, Brenner ZA, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524\u201348.","journal-title":"JAMA Oncol."},{"issue":"2","key":"925_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1053\/j.seminoncol.2005.12.013","volume":"33","author":"PD Wadhwa","year":"2006","unstructured":"Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):240\u20139.","journal-title":"Semin Oncol"},{"key":"925_CR5","unstructured":"British Columbia SID Working Group. Secondary Immunodeficiency\u2014Ig Dose and Schedule. July 2021. https:\/\/www.pbco.ca\/index.php\/programs\/immunodeficiency\/secondary-immunodeficiency Accessed November 2, 2023."},{"key":"925_CR6","unstructured":"British Columbia SID Working Group. Secondary Immunodeficiency\u2014Indications for Ig Use. July 2021. https:\/\/www.pbco.ca\/index.php\/programs\/immunodeficiency\/secondary-immunodeficiency Accessed November 2, 2023."},{"key":"925_CR7","unstructured":"Rituxan (rituximab) product monograph. Hoffman-La Roche Ltd. June 2, 2023."},{"key":"925_CR8","unstructured":"Gazyva (obinutuzumab) product monograph. Hoffmann-La Roche Ltd. July 25, 2022."},{"key":"925_CR9","unstructured":"Zevalin (ibritumomab tiuxetan) product monograph. Servier Canada Inc. August 11, 2016."},{"key":"925_CR10","unstructured":"Kesimpta (ofatumumab) product monograph. Novartis Pharmaceuticals Canada Inc. March 1, 2023."},{"key":"925_CR11","unstructured":"Ocrevus (ocrelizumab) product monograph. Hoffmann-La Roche Ltd. January 9, 2023."},{"key":"925_CR12","unstructured":"Briumvi (ublituximab). Prescribing information. TG Therapeutics Inc; 2022."},{"key":"925_CR13","unstructured":"Blincyto (blinatumomab) product monograph. Amgen Canada Inc. August 29, 2023."},{"key":"925_CR14","unstructured":"Besponsa (inotuzumab) product monograph. Pfizer Canada Inc. March 15, 2018."},{"key":"925_CR15","unstructured":"Lemtrada (alemtuzumab) product monograph. Sanofi Genzyme. May 17, 2023."},{"key":"925_CR16","unstructured":"Darzalex (daratumumab) product monograph. Janssen Inc. May 29, 2023."},{"key":"925_CR17","unstructured":"Sarclisa (isatuximab) product monograph. Sanofi-aventis Canada Inc. May 11, 2023."},{"key":"925_CR18","unstructured":"Benlysta (belimumab) product monograph. GlaxoSmithKline Inc. May 23, 2023."},{"issue":"1","key":"925_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1042\/CS20210344","volume":"136","author":"M Chauvin","year":"2022","unstructured":"Chauvin M, Sauce D. Mechanisms of immune aging in HIV. Clin Sci (Lond). 2022;136(1):61\u201380.","journal-title":"Clin Sci (Lond)"},{"key":"925_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coviro.2020.08.002","volume":"46","author":"DE Griffin","year":"2021","unstructured":"Griffin DE. Measles immunity and immunosuppression. Curr Opin Virol. 2021;46:9\u201314.","journal-title":"Curr Opin Virol"},{"key":"925_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.742941","volume":"12","author":"LY Tan","year":"2021","unstructured":"Tan LY, Komarasamy TV, Rmt BV. Hyperinflammatory immune response and COVID-19: a double edged sword. Front Immunol. 2021;12: 742941.","journal-title":"Front Immunol"},{"issue":"23","key":"925_CR22","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255\u201373.","journal-title":"N Engl J Med"},{"issue":"1","key":"925_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jmv.26232","volume":"93","author":"B Hu","year":"2021","unstructured":"Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93(1):250\u20136.","journal-title":"J Med Virol"},{"issue":"3","key":"925_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133\u201346.","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"925_CR25","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s41579-022-00763-4","volume":"20","author":"P Chandra","year":"2022","unstructured":"Chandra P, Grigsby SJ, Philips JA. Immune evasion and provocation by Mycobacterium tuberculosis. Nat Rev Microbiol. 2022;20(12):750\u201366.","journal-title":"Nat Rev Microbiol"},{"key":"925_CR26","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3389\/fimmu.2020.00899","volume":"11","author":"MES Sampah","year":"2020","unstructured":"Sampah MES, Hackam DJ. Dysregulated mucosal immunity and associated pathogeneses in preterm neonates. Front Immunol. 2020;11:899.","journal-title":"Front Immunol"},{"issue":"2","key":"925_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.earlhumdev.2010.11.003","volume":"87","author":"JP van den Berg","year":"2011","unstructured":"van den Berg JP, Westerbeek EA, van der Klis FR, Berbers GA, van Elburg RM. Transplacental transport of IgG antibodies to preterm infants: a review of the literature. Early Hum Dev. 2011;87(2):67\u201372.","journal-title":"Early Hum Dev"},{"key":"925_CR28","doi-asserted-by":"publisher","first-page":"S422","DOI":"10.1513\/AnnalsATS.201602-095AW","volume":"13","author":"CM Weyand","year":"2016","unstructured":"Weyand CM, Goronzy JJ. Aging of the immune system. mechanisms and therapeutic targets. Ann Am Thorac Soc. 2016;13:S422\u20138.","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"925_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.blre.2017.09.003","volume":"32","author":"M Ueda","year":"2018","unstructured":"Ueda M, Berger M, Gale RP, Lazarus HM. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. Blood Rev. 2018;32(2):106\u201315.","journal-title":"Blood Rev"},{"key":"925_CR30","unstructured":"Canadian Blood Services. Product comparison tables: IV immune globulins and SC immune globulins. 2018. https:\/\/www.blood.ca\/en\/hospital-services\/products\/plasma-protein-and-related-products Accessed November 10, 2023."},{"key":"925_CR31","unstructured":"Hema Quebec. https:\/\/www.hema-quebec.qc.ca\/sang\/professionnels-sante\/produits-sanguins-stables\/index.en.html Accessed December 21, 2023."}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-024-00925-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-024-00925-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-024-00925-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:43:37Z","timestamp":1748360617000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-024-00925-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":31,"journal-issue":{"issue":"S3","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1186\/s13223-024-00925-4","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate are not applicable to this review article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Persia\u00a0Pourshahnazari has received consulting fees and honoraria from Takeda, CSL Behring, Grifols, Octapharma, AstraZeneca, Novartis, Sanofi, Valeo Pharma, Bausch Healthcare, ALK, and Stallergenes Greer. Dr. Stephen D. Betschel has received consulting fees, honoraria, and research funding from Astria, Canadian Blood Services, CSL Behring, Green Cross, Grifols, Ionis Pharmaceuticals, Kalvista Novartis, Octapharma, Pharvaris, Sanofi, Takeda, and WSIB. Dr. Vy H.D. Kim is a medical advisory board member of Immunity Canada and is a clinical trial investigator for ALK-Abello and DBV Technologies. Dr. Susan Waserman has received consulting fees and honoraria from AstraZeneca, GlaxoSmithKline, Novartis, ALK, Bausch Health, Mylan, Meda, CSL Behring, Sanofi, Takeda, Pfizer, Sanofi, Medexus Pharma, and Miravo. She is a clinical trial investigator for Aimmune. She is the President of the Canadian Allergy, Asthma and Immunology Foundation (CAAIF), and medical advisor to Food Allergy Canada. Dr. Rongbo Zhu has received consulting fees\/honoraria from ALK, AstraZeneca, Bausch Health, GlaxoSmithKline, Medexus Pharmaceuticals, Sanofi, Stallergenes Greer, ValeoPharma. Dr. Harold Kim has received honoraria and\/or consulting fees from ALK, AstraZeneca, Bausch Health, CSL Behring, GSK, Miravo, Novartis, Medexus, Pfizer, Sanofi, Shire, Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}